The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2025 | Exploring future applications of SENTI-202, an off-the-shelf allogeneic CAR-NK therapy
In this video, Stephen Strickland, MD, SCRi at TriStar Bone Marrow Transplant, Nashville, TN, comments on the potential future role of SENTI-202, an off-the-shelf allogeneic CAR-NK therapy, in the treatment landscape of hematologic malignancies. Although all patients enrolled in the Phase I clinical trial (NCT06325748) investigating this product have acute myeloid leukemia (AML), Dr Strickland highlights the opportunity to extend this therapy to other CD33-positive malignancies, such as myelodysplastic syndromes (MDS) and mixed phenotype acute leukemia (MPAL). He also suggests that SENTI-202 could be effective in earlier lines of treatment, potentially as a consolidative therapy for patients in first remission. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As of now, we have enrolled only AML patients, and that’s by chance, not necessarily by design or restriction, but just as it is, the first nine patients that have been enrolled are all AML patients. So I think that obviously continuing to understand the response patterns and the activity within the AML population, but also extending this to other CD33 positive malignancies as well, such as MDS, and even potentially mixed phenotype acute leukemia, in which we know we are very desperate to have effective therapies for that population as well...
As of now, we have enrolled only AML patients, and that’s by chance, not necessarily by design or restriction, but just as it is, the first nine patients that have been enrolled are all AML patients. So I think that obviously continuing to understand the response patterns and the activity within the AML population, but also extending this to other CD33 positive malignancies as well, such as MDS, and even potentially mixed phenotype acute leukemia, in which we know we are very desperate to have effective therapies for that population as well. So I think that we can extend a broader net as we continue to enroll onto the study about other disease subtypes, specifically or primarily myeloid disease subtypes, where this may provide potential benefit.
But in addition to that, I think it’s also where do we use it, right? This is a therapy which is currently being used in a more heavily pretreated population, patients that have failed prior therapy, and in some cases even failed prior allogeneic stem cell transplantation, and yet the disease has still relapsed. And we’re seeing activity in these patients. So, the natural progression is also to say, well, if we see it in heavily pretreated patients, can patients benefit from this even in earlier lines of therapy. And so could we potentially use this as a consolidative aspect, even for patients in the first remission potentially is one potential opportunity. So I think having an effective therapy in a heavily pretreated relapsed/refractory population, that’s wonderful. But I think to optimize it, if we can get this more effective therapy earlier to patients, and can we actually translate not just to remissions, but actually to cures, and I think that’s where the possibility potentially exists.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
